A Study of TAK-341 in Treatment of Multiple System Atrophy
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system
atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
The study will enroll approximately 138 patients. Participants will receive a total of 13
intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo,
after each infusion some blood samplings will be taken and other assessments completed.
This trial will be conducted in North America, Europe and Asia.